Duc Tran, MSc

Duc brings over 25 years of drug development experience spanning a broad range of therapeutic areas, including cardiovascular, anti-infective, urology, epigenetics, CNS, reproductive medicine, autoimmune diseases, and oncology. His experience covers the full drug development continuum, from lead optimization through pivotal Phase III clinical development stages. Duc has built this expertise through senior roles in both large pharmaceutical companies, including Sanofi-Aventis, Pfizer, and Lundbeck, and innovative biotech companies such as Preglem (acquired by Gedeon Richter), Arisgen, EspeRare, Prexton Therapeutics (acquired by Lundbeck), Calypso Biotech (acquired by Novartis) and Step Pharma. He has successfully advanced multiple programs from early development through clinical development.

Duc graduated from the French Grandes Écoles d’ingénieurs ESPCI with training in Physics, Chemistry, and Biology. He also holds an MSc in organic and bio-organic chemistry from Université Paris VI.

‍